Scientific deep-dive
Does Semaglutide Slow Aging?
A trial reported semaglutide slowing epigenetic aging across several clocks. It was a post hoc analysis in an HIV-specific cohort over 32 weeks, and '−4.9 years per year' is a rate, not age removed.
A randomized trial reported that semaglutide slowed epigenetic aging across several biological-age clocks.[1] That sentence is going to travel a very long way, so here is what sits under it: a post hoc analysis, in people with HIV-associated lipohypertrophy, over 32 weeks — limitations the authors list themselves.
What was measured
Researchers took whole-blood DNA methylation at baseline and week 32 and ran it through first-, second- and third-generation epigenetic clocks — algorithms that estimate biological age from chemical marks on DNA. In adjusted analyses semaglutide reduced aging across several of them.[1]
| Clock | Change | p |
|---|---|---|
| PhenoAge | −4.9 years/year | 0.004 |
| PCGrimAge | −3.1 | 0.007 |
| GrimAge V2 | −2.3 | 0.009 |
| OMICmAge | −2.2 | 0.009 |
| RetroAge | −2.2 | 0.030 |
| DunedinPACE | −0.09 units (9% slower) | 0.01 |
Systems-based clocks showed parallel reductions in inflammation, brain and heart aging measures.[1]
The units are the trap
“Minus 4.9 years per year” is a change in rate. It is not 4.9 years removed from anybody.
That distinction disappears in almost every popular retelling of studies like this. What the number describes is how fast an estimate of biological age was moving, not a quantity of age subtracted. DunedinPACE makes it clearest: 9% slower, expressed as a pace rather than a total.
What an epigenetic clock is, and is not
These clocks are statistical models trained to predict outcomes — mortality, disease onset, functional decline — from methylation patterns. They are impressive and they are estimates. A clock reading is not a measurement of aging in the way a blood pressure is a measurement of pressure.
Which makes this a surrogate endpoint, and surrogates have a long record of moving while outcomes stay put. We covered the same problem with inflammatory markers in tirzepatide and inflammation: hsCRP falls reliably, and whether anything happens to a person as a result is a separate question nobody has answered.
The limits, in the authors' own list
- Post hoc design. The aging question was asked of data collected for another purpose.
- Modest sample size.
- An HIV-specific cohort with lipohypertrophy — a population with distinctive metabolic and inflammatory biology.
- 32 weeks. For an aging question, that is a very short window.
The authors’ own conclusion is that prospective trials are needed to determine whether GLP-1 receptor agonists can be repurposed as gerotherapeutics.[1] That is the correct position, and it is several steps short of what the headline implies.
It is also worth remembering how the last big “beyond weight” hypothesis in this class fared. Two randomized trials of semaglutide in early Alzheimer’s disease, in 3,808 people, found nothing at all. Mechanistic promise in this drug class has repeatedly not survived a proper test.
Frequently Asked Questions
References
- 1.Corley MJ, Dwaraka VB, Pang AP, et al. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy Nature Communications. 2026. PMID: 42156721.
Compare the sellers
Related research
Beyond the Scale: Blood Pressure, Lipids and What Else Changes
Pooling the individual records of 3,136 people, systolic blood pressure fell 4.95 mmHg further than placebo, and by about the same amount whether or not the person had hypertension.
7 min read
Dry Mouth on a GLP-1: Three Published Cases, and What to Tell Your Dentist
The published evidence that GLP-1 drugs cause dry mouth is three case reports. Nobody has measured how often it happens, but reduced saliva raises decay risk regardless of cause, which is the part worth acting on.
5 min read
Eating Too Little on a GLP-1: What the Deficiency Data Show
Across 480,825 adults, more than 60% were consuming below estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.
7 min read
Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went
Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. One generic remains.
10 min read
GLP-1 Drugs After 65: Strength, Not Just Weight
Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite, and no guidelines exist for this age group.
7 min read
GLP-1 Drugs After Spinal Cord Injury: Three People Treated, Two Not
In a controlled case series of five people with chronic spinal cord injury, three on weekly semaglutide lost weight, fat mass and visceral fat over 26 weeks while the two untreated participants gained on every measure.
5 min read
Where to get semaglutide (Ozempic / Wegovy) online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Bodybuilding Health+
Seeing what it charges before you answer any medical questions
From $179/mo
Get started →ShedRx
Oral orforglipron alongside the injectables
From $149/mo
Get started →bmiMD
Starting below a standard dose, with microdose tiers
From $99/mo
Get started →